Who is sponsoring NCT00866840?

NCT00866840 is sponsored by Rutgers, The State University of New Jersey.

What condition does NCT00866840 study?

NCT00866840 studies Melanoma (Skin).

What is the status of NCT00866840?

NCT00866840 is currently COMPLETED.

Last reviewed 2024-01-17 · How we verify

A Phase II Trial of Riluzole in Patients With Advanced Melanoma

NCT00866840 Phase 2 COMPLETED Results posted

RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.

Details

Lead sponsor	Rutgers, The State University of New Jersey
Phase	Phase 2
Status	COMPLETED
Enrolment	13
Start date	2009-04
Completion	2013-07

Conditions

Melanoma (Skin)

Interventions

riluzole

Primary outcomes

Tumor Response as Measured by RECIST Criteria — Imaging for tumor assessments was performed after 6 weeks
Per Response Evaluation Criteria in Solid Tumors (RECIST v1.0) for target lesions and assessed by CT or MRI imaging: Complete response (CR) - disappearance of all target lesions; Partial response (PR) - \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) - At least a 20% increase in the sum of the longest diameter of target lesions; or Stable Disease (SD) - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Countries

United States